Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7992434 | 0.84 | TRPA1 (0.43) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL18103172 | 0.82 | TRPA1 (0.42) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL17767222 | 0.82 | PDE2A (0.58) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL13345087 | 0.82 | TRPA1 (0.47) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL20811584 | 0.82 | PDE2A (0.58) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL17769044 | 0.82 | PDE2A (0.58) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL84060 | 0.81 | TRPA1 (0.50) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL8981744 | 0.81 | TRPA1 (0.40) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL13826610 | 0.80 | PDE2A (0.59) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| Hydrochloric Acid SCHEMBL20790469 | 0.80 | PDE2A (0.56) | TRPA1LMNACHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024145569-A2 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024126117-A1 | PYRIMIDINONE DERIVATIVES AS PESTICIDAL COMPOUNDS | BASF SE (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | SIMONEAU BRUNO | 2007-09-27 | — | — | US | disclosed |
| US-20070219176-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885LMNA 170/4885CHRM1 3754/4885 |
| US-20070219176-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | TRPA1 4809/4885LMNA 3643/4885CHRM1 4427/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | TRPA1 345/4885LMNA 2312/4885CHRM1 1248/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885LMNA 170/4885CHRM1 3754/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | TRPA1 953/4885LMNA 2472/4885CHRM1 1300/4885 |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | TRPA1 3049/4885LMNA 3537/4885CHRM1 4870/4885 |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | TRPA1 4596/4885LMNA 3886/4885CHRM1 4671/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | TRPA1 4876/4885LMNA 2226/4885CHRM1 3828/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | TRPA1 3274/4885LMNA 1676/4885CHRM1 1407/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | TRPA1 3/4885LMNA 3442/4885CHRM1 3659/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | TRPA1 4584/4885LMNA 2727/4885CHRM1 4874/4885 |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | POLR2E, POLR2H, POLR2A | TRPA1 4537/4885LMNA 2603/4885CHRM1 1471/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | TRPA1 3610/4885LMNA 1527/4885CHRM1 888/4885 |
| US-20070060572-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | TRPA1 3790/4885LMNA 2007/4885CHRM1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.